Travere Therapeutics, Inc. (TVTX) fair value analysis
Nasdaq · Updated 2026-09-07
Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and commercializing medicines for rare kidney diseases and other serious conditions. The company operates primarily in the United States and serves patients globally through its research, development, and commercial operations.
Valuation status
Awaiting full valuationTVTX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $54.98
- Sector
- Healthcare
- 12-month range
- $24.79–$56.34
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- High
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The top quarter of its range
What our data shows for TVTX
- Our model validated 3 trailing price-to-earnings windows for TVTX, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $24.79–$56.34.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TVTX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent TVTX news
TickrTrends' derived news-sentiment signal for TVTX is currently mixed, computed from recent coverage.
- Travere Therapeutics: Valuation Suggests A Buy (NASDAQ:TVTX) (seekingalpha.com, 2026-08-19)
TickrTrends take: Travere Therapeutics operates in the Healthcare sector where valuation multiples can vary significantly based on pipeline progress and revenue stability. TickrTrends is currently awaiting full valuation data for TVTX, meaning a complete picture of its relative value compared to sector peers has not yet been established. Investors focused on valuation metrics should monitor when complete financial analysis becomes available, as this will provide essential context for comparing TVTX's price relative to its fundamentals and growth prospects within the healthcare industry. - Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again) (NASDAQ:TVTX) (seekingalpha.com, 2026-08-06)
TickrTrends take: Travere Therapeutics is currently in a valuation-awaiting status on TickrTrends, meaning a comprehensive assessment of its fair value has not yet been completed. The recent earnings-driven downgrade to Hold signals potential concerns about the company's near-term prospects that could influence how its valuation is ultimately determined when that analysis is completed. Valuation-focused investors monitoring this Healthcare sector company should pay attention to whether upcoming quarterly results and revenue trends support or challenge the reasons behind the recent rating adjustment.
What people are saying
Follow the TVTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TVTX stock undervalued?
TVTX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is TVTX's TickrTrends verdict?
TVTX is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is TVTX overbought or oversold?
TVTX's 14-day RSI is in neutral territory - neither overbought nor oversold.